UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
ARGENTUM PHARMACEUTICALS LLC,
Petitioner  v.
ALLERGAN, INC. Patent Owner
Case IPR2016-01232 Patent 8,629,111

## JOINT REQUEST TO TREAT SETTLEMENT AGREEMENT AS <u>BUSINESS CONFIDENTIAL INFORMATION</u>



Case No.: IPR2016-01232

Joint Request to Keep Settlement Agreement Confidential

Petitioners Argentum Pharmaceuticals LLC and Allergan, Inc. request that the settlement and license agreement submitted concurrently herewith be treated as business confidential information and kept separate from the files of the involved patent and *inter partes* review proceeding in accordance with 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c) and only made available to Federal Government agencies upon written request or to any other person upon written request and a showing of good cause.

Respectfully submitted,

Date:/December 7, 2016/

/Dorothy P. Whelan/

Dorothy P. Whelan, Reg. No. 33,814 Michael J. Kane, Reg. No. 39,722 Attorneys for Allergan, Inc.

/Matthew J. Dowd/

Matthew J. Dowd, Reg. No. 47,534

Attorney for Argentum Pharmaceuticals LLC.



## CERTIFICATE OF SERVICE

Pursuant to 37 CFR §§ 42.6(e)(4) and 42.205(b), the undersigned certifies that on December 7, 2016, a complete and entire copy of this Joint Request to Keep Settlement Agreement Confidential was provided via electronic service, to the Petitioner by serving the correspondence address of record as follows:

Matthew J. Dowd
Tyler C. Liu
Dowd PLLC
1717 Pennsylvania Avenue, NW, Suite 1025
Washington, D.C. 20006
mjdowd@dowdpllc.com

/Diana Bradley/

Diana Bradley Fish & Richardson P.C. 60 South Sixth Street, Suite 3200 Minneapolis, MN 55402 (858) 678-5667

